ReShape Lifesciences (RSLS) Q2 2024 earnings summary

Executive summary

• Achieved a 45.4% reduction in operating expenses in H1 2024, stabilizing gross profit margin despite lower sales from increased GLP-1 adoption.

• Entered into a definitive merger agreement with Vyome Therapeutics and an asset sale agreement with Biorad for $5.16 million in cash, aiming to maximize shareholder value.

• Series C preferred stockholders agreed to substantially lower their liquidation preference, enhancing value for common stockholders.

• Net loss for Q2 2024 was $1.6 million, improved from $3.5 million in Q2 2023, driven by cost reductions.

• Substantial doubt exists about the ability to continue as a going concern, with cash expected to run out during Q3 2024 without additional funding or completion of planned transactions.

Financial highlights

• Q2 2024 revenue was $2.0 million, down 12.8% year-over-year; six-month revenue was $3.9 million, down 13.9%.

• Q2 2024 gross profit was $1.1 million (57.7% margin), slightly below Q2 2023 but with improved margin due to cost reductions.

• Adjusted EBITDA loss for Q2 2024 was $1.9 million, improved from $3.7 million last year; six-month loss was $4.1 million, improved from $9.1 million.

• Cash and cash equivalents as of June 30, 2024, were $1.2 million, with net working capital of $2.9 million; company remained debt-free.

• Operating expenses decreased 38.3% year-over-year in Q2 2024, mainly from lower sales/marketing and G&A costs.

Outlook and guidance

• Management expects the merger with Vyome and asset sale to Biorad to unlock significant shareholder value and growth potential for the combined entity.

• Expects to self-fund operations into the second half of 2025 based on anticipated cash flow and new capital commitments, but projects running out of cash during Q3 2024 if transactions do not close.

• Plans for a widespread commercial launch of Lap-Band 2.0 FLEX following successful limited market release.